Copyright
©The Author(s) 2018.
World J Clin Cases. Apr 16, 2018; 6(4): 44-53
Published online Apr 16, 2018. doi: 10.12998/wjcc.v6.i4.44
Published online Apr 16, 2018. doi: 10.12998/wjcc.v6.i4.44
Table 3 Multivariate analysis
OR | CI | P value | |
Gender | 1.48 | 0.83-2.67 | 0.188 |
Alkaline phosphatase | 1.00 | 0.99-1.01 | 0.282 |
Albumin | 0.96 | 0.92-1.01 | 0.108 |
Current smoking status | 0.42 | 0.17-0.91 | 0.041 |
Azathioprine treatment | 1.57 | 0.873-2.79 | 0.128 |
Prednisone treatment | 1.15 | 0.53-2.36 | 0.707 |
Vitamin D supplement | 0.72 | 0.29-1.79 | 0.471 |
Vitamin E supplement | 4.36 | 0.56-24.46 | 0.110 |
Calcium supplement | 2.36 | 1.00-5.21 | 0.040 |
Thrombosis | 1.38 | 0.19-5.89 | 0.701 |
- Citation: Girardin M, Hadengue A, Frossard JL, the Swiss IBD Cohort Study Group. High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients. World J Clin Cases 2018; 6(4): 44-53
- URL: https://www.wjgnet.com/2307-8960/full/v6/i4/44.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i4.44